Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Liraglutide The FDA approved Novo Nordisks Victoza for Type 2 diabetes in 2010 and Saxenda for obesity in 2014
They are most likely during initiation and dose increases and improve for most people once the maintenance dose is reached
The Phase 2 DXA sub-study published in June 2025 provides the first retatrutide body composition data, but direct comparison to semaglutide's DXA data requires caution due to differences in study populations, duration, and design
So even if the medications themselves represent good value for society, that does not mean we, as a society, can take the impact of how many individuals would use this. According to the Centers for Disease Control and Prevention, some 40% of Americans are obese
